Treatment Options in Refractory Autoimmune Encephalitis
Open Access
- 2 August 2022
- journal article
- research article
- Published by Springer Nature in CNS Drugs
- Vol. 36 (9) , 919-931
Abstract
Autoimmune encephalitis represents a potentially treatable immune-mediated condition that is being more frequently recognized. Prompt immunotherapy is a key factor for the management of autoimmune encephalitis. First-line treatments include intravenous steroids, plasma exchange, and intravenous immunoglobulins, which can be combined in most severe cases. Rituximab and cyclophosphamide are administered as second-line agents in unresponsive cases. A minority of patients may still remain refractory, thus representing a major clinical challenge. In these cases, treatment strategies are controversial, and no guidelines exist. Treatments proposed for refractory autoimmune encephalitis include (1) cytokine-based drugs (such as tocilizumab, interleukin-2/basiliximab, anakinra, and tofacitinib); (2) plasma cell-depleting agents (such as bortezomib and daratumumab); and (3) treatments targeting intrathecal immune cells or their trafficking through the blood–brain barrier (such as intrathecal methotrexate and natalizumab). The efficacy evidence of these drugs is mostly based on case reports or small case series, with few reported controlled studies or systematic reviews. The aim of the present review is to summarize the current evidence and related methodological issues in the use of these drugs for the treatment of refractory autoimmune encephalitis.Keywords
Funding Information
- Università degli Studi di Verona
This publication has 78 references indexed in Scilit:
- Intrathecal treatment of anti‐N‐Methyl‐d‐aspartate receptor encephalitis in childrenDevelopmental Medicine & Child Neurology, 2014
- Effect of Rituximab in Patients With Leucine-Rich, Glioma-Inactivated 1 Antibody–Associated EncephalopathyJAMA Neurology, 2014
- Long-term remission with rituximab in refractory leucine-rich glioma inactivated 1 antibody encephalitisJournal of Neuroimmunology, 2014
- Methotrexate-Induced Neurotoxicity and Leukoencephalopathy in Childhood Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2014
- Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotypeBrain, 2013
- Successful Treatment of Anti-Caspr2 Syndrome by Interleukin 6 Receptor Blockade Through TocilizumabJAMA Neurology, 2013
- Prevalence and treatment of anti-NMDA receptor encephalitisThe Lancet Neurology, 2013
- Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort studyThe Lancet Neurology, 2013
- A Low Interleukin-2 Receptor Signaling Threshold Supports the Development and Homeostasis of T Regulatory CellsImmunity, 2009
- A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple SclerosisNew England Journal of Medicine, 2006